Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER-2/neu Positive Breast Cancer

BACKGROUND. Among women with surgically removed, high-risk HER-2/neu-positive breast cancer, trastuzumab has demonstrated significant improvements in disease-free and overall survival. The objective of this study is to evaluate the cost-effectiveness of the currently recommended 12-month adjuvant pr...

Full description

Saved in:
Bibliographic Details
Main Authors: Hedden, Lindsay, O'Reilly, Susan, Lohrisch, Caroline, Chia, Stephen, Speers, Caroline, Kovacic, Laurel, Taylor, Suzanne, Peacock, Stuart
Format: Artigo
Language:Inglês
Published: AlphaMed Press 2012
Subjects:
Breast Cancer
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3286164/
https://ncbi.nlm.nih.gov/pubmed/22302231
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0379
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items